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Purpose: In the recent antiretroviral therapy (ART) era, a large proportion of Korean patients with human immunodeficiency vi-
rus (HIV) infection were shown to have low CD4 cell counts at diagnosis and during ART initiation. We investigated the survival 
trends in patients living with HIV/acquired immunodeficiency syndrome (AIDS) in Korea who started ART in the 2000s, and 
evaluated the risk factors for mortality to elucidate the association between survival and low CD4 cell counts at ART initiation.
Materials and Methods: Patients with HIV infection who were aged >18 years and had started ART between 2001 and 2015 in the 
Korean HIV/AIDS cohort study were enrolled. We compared the clinical characteristics, mortality, and causes of death among 
the enrolled subjects based on the time of ART initiation. Cox regression analysis was used to estimate the adjusted hazard ratios 
of mortality based on the time of ART initiation.
Results: Among the 2474 patients enrolled, 105 (4.24%) died during the follow-up period of 9568 patient-years. Although CD4 cell 
counts at the time of ART initiation significantly increased from 161 [interquartile range (IQR), 73.5–303] in 2001–2003 to 273 (IQR, 
108–399) in 2013–2015 (p<0.001), they remained low during the study period. The incidence of all-cause mortality was 10.97 per 
1000 patient-years during the study period. There was no decreasing trend in mortality between 2001 and 2015. Age >40 years [ad-
justed hazard ratio, 3.71; 95% confidence interval (CI), 2.35–5.84] and low CD4 counts (<100 cells/mm3: adjusted hazard ratio, 
2.99; 95% CI, 1.44–6.23) were significant risk factors for mortality.
Conclusion: Despite excellent HIV care available in the recent ART era, the survival of patients with HIV/AIDS undergoing ART 
did not improve between 2001 and 2015 in Korea.
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INTRODUCTION
The overall survival of patients with human immunodeficiency 
virus (HIV) infection has improved after the introduction and 
rapid evolution of antiretroviral therapy (ART) over the recent 
decades.1-4 Currently available ART is more effective in viral 
suppression and less toxic than early ART, with fewer adverse 
effects. Moreover, patient care, in terms of screening, prophy-
laxis, and treatment for comorbidities, has improved. Therefore, 
the life expectancy of patients successfully treated with ART has 
become closer to that of the general population at similar ages.5 
This might be related to the patients’ increased risk of comor-
bidities associated with age, such as cardiovascular disease or 
cancer, which has altered the cause of death. The mortality at-
tributed to acquired immunodeficiency syndrome (AIDS)-de-
fining disease has declined, whereas the proportion of deaths 
due to non-AIDS causes has increased.6-8
In Korea, although the prevalence and incidence of HIV in-
fection have remained low since the first case of HIV infection 
reported in 1985, the number of newly confirmed HIV infections 
has steadily increased every year. According to the Korea Cen-
ters for Disease Control and Prevention (KCDC), the number 
of new infections has increased rapidly since 2010, exceeding 
1000 for the first time in 2013 and reaching 1199 in 2016. As a re-
sult, the cumulative figure was 121320 in 2017. Men accounted 
for 95% of the infected individuals, and sexual contact was the 
major route of infection (>99%).9 ART for patients with HIV in-
fection has been scaled up rapidly in Korea over the past 20 years, 
since the introduction of zidovudine in the country in 1991. Cur-
rently, patients with HIV infection are treated with various ART 
combinations without much financial burden in Korea due to 
national support. In the early ART era, treatment was initiated 
when the CD4 cell count was below a certain level, or in the pres-
ence of any AIDS-related symptoms. The revised guidelines, 
published in Korea in 2013, recommend the initiation of treat-
ment after the diagnosis of HIV infection, regardless of the CD4 
cell count.10
In the recent era, improved survival of HIV patients is expect-
ed in Korea, owing to the modifications in ART, the national fi-
nancial support for HIV treatment, as well as the changes in the 
guidelines for initiating ART. However, whether there have been 
actual improvements in survival remains arguable, as the pro-
portion of patients with CD4 cell counts ≤200 cells/mm3 at di-
agnosis and during ART initiation has increased in the late ART 
era.11 Here, we investigated the recent trends in the survival of 
patients living with HIV/AIDS in Korea who started ART be-
tween 2001 and 2015. This study also evaluated the risk factors 
for mortality to elucidate the association between survival and 
low CD4 cell counts at ART initiation.
MATERIALS AND METHODS
Study design and participants
We collected data from the Korea HIV/AIDS Cohort Study, a pro-
spective observational cohort study including patients diagnosed 
with HIV infection from 21 hospitals in Korea. The Korea HIV/
AIDS Cohort Study was established in 2006, and we used the 
data from the baseline and repeated surveys that were collect-
ed from December 2006 to December 2016. At the time of base-
line survey, we examined the events that occurred throughout 
the patient’s lifetime or on the basis of HIV infection diagnosis. 
Repeated surveys were conducted, and trained researchers col-
lected data on the events identified since the last survey using 
a standardized protocol every 6 months. Data on demographic 
characteristics were collected using a self-reported question-
naire. Data on antiretroviral treatment and adherence, as well 
as chronic and other diseases, were collected through patient 
interviews and from medical records. Participants who were lost 
to follow-up were investigated using nationally reported data to 
determine whether those participants had died. Additionally, 
we analyzed the data obtained from the Korea HIV/AIDS Retro-
spective Cohort Study, which included 2663 patients with HIV 
infection who never participated in the Korea HIV/AIDS Cohort 
Study from December 2006 to August 2016. Data were collected 
from medical records obtained from the 12 participating univer-
sity-affiliated hospitals. We combined the data from both the 
Korea HIV/AIDS Cohort Study and the Korea HIV/AIDS Retro-
spective Cohort Study.
Patients aged >18 years who were confirmed as HIV-positive 
by Western blot tests were eligible for inclusion in this study. 
We included patients who received their initial ART between 
2001 and 2015, and visited at least one participating hospital. 
Those who started ART with mono or dual regimens prior to a 
triple-drug regimen were also included. Participants were fol-
lowed up from the time of ART initiation. All participants in the 
prospective cohort provided their written informed consent. 
Both cohort studies received ethical approval from the Institu-
tional Review Boards of their respective participating institutes.
Data collection
We collected data from both cohorts at the time of ART initia-
tion. The following variables were investigated: age, sex, medi-
an CD4 cell counts at the time of initial ART, median HIV viral 
load at the time of initial ART, median time from HIV infection 
diagnosis to ART initiation, year of HIV infection diagnosis, and 
year of ART initiation. Causes of death were classified into cat-
egories according to CoDe Project protocol.12 Deaths were clas-
sified as AIDS-related if there was a close association between 
death and AIDS-defining conditions based on the definition 
provided by the Centers for Disease Control and Prevention.13 
Deaths were also considered to be AIDS-related if patients had 
CD4 cell counts ≤200 cells/mm3 at the time of death. Non-AIDS-
related deaths were grouped into those caused by infection, 
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liver disease, malignancy, cardiovascular disease, respiratory 
disease, accident/suicide/overdose, and others.12 Information 
about the cause of death was obtained from the AIDS Manage-
ment Division of the KCDC, as well as from each participating 
hospital. 
Statistics
Descriptive statistics were used to summarize the causes of 
death and clinical characteristics at the time of ART initiation 
according to the year of ART initiation (2001–2003, 2004–2006, 
2007–2009, 2010–2012, and 2013–2015). The Cochran-Armitage 
test for trend was used to determine if there was an association 
between the period of ART initiation and sex. The Jonckheere-
Terpstra test was used to determine if there was a statistically 
significant association between the period of ART initiation and 
continuous dependent variables, including median age at the 
time of initial ART, median CD4 cell counts/viral loads at the 
time of initial ART, and median time to treatment. To identify a 
trend in the mortality rate according to the period of ART ini-
tiation between 2001 and 2015, we conducted the Mann-Ken-
dall trend test. We used a Cox regression model to analyze the 
risk factors associated with all-cause mortality. The beginning 
time point of follow-up was initial ART starting date, and follow-
up ended at the date when a participant died. All other partic-
ipants were censored at the date of their last follow-up visit to 
the participating clinic. Variables found to be significant in uni-
variate analysis were included in the multivariate model. The 
relationship between risk factors and mortality were summa-
rized by hazard ratios (HR) and 95% confidence intervals (CI). 
Continuous variables were presented as medians with inter-
quartile ranges (IQR), and categorical variables were expressed 
as numbers with percentages. Statistical analyses were per-




A total of 3167 participants started ART between 2001 and 2015. 
Of these, 693 participants were excluded due to missing data for 
age, CD4 cell counts/viral loads at the time of initial ART, period 
from HIV infection diagnosis to initial ART, or follow-up dura-
tion from the initial ART to death. Thus, a total of 2474 patients 
with HIV infection who started ART between 2001 and 2015 were 
included (Fig. 1). The proportion of women was 15.3% in 2001–
2003; however, it decreased to 6% in 2013–2015 (p for trend= 
0.001). The median age decreased from 39 years (IQR 32–44.5 
years) in 2001–2003 to 36 years (IQR 28–47 years) in 2013–2015 
(p for trend <0.001). Although the median CD4 cell counts at 
the time of ART initiation increased from 161 cells/mm3 (IQR 
73.5–303 cells/mm3) in 2001–2003 to 273 cells/mm3 (IQR 108–
399 cells/mm3) in 2013–2015 (p for trend <0.001), they remained 
low during the study period. There was no significant trend be-
tween the period of ART initiation and median HIV viral loads 
(p for trend=0.379). The median HIV viral loads varied accord-
ing to the period of ART initiation [73316 (IQR 21601–191500), 
50000 (IQR 9700–210000), 48000 (IQR 8520–161000), 65232 (IQR 
16300–200000), and 45350 (IQR 11101–157770) copies/mL in 
2001–2003, 2004–2006, 2007–2009, 2010–2012, and 2013–2015, 
Fig. 1. Flow diagram of study process. HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy.
Korea HIV/AIDS Cohort Study (December 2006 to December 2016)
n=1442
Korea HIV/AIDS Retrospective Cohort Study (December 2006 to August 2016)
n=2663
People starting ART between 2001 and 2015 in the Korea HIV/AIDS Cohort Study
n=1214
Study population (Korea HIV/AIDS Cohort Study: 1031, 
Korea HIV/AIDS Retrospective Cohort Study: 1443)
n=2474
People starting ART between 2001 and 2015 in the Korea HIV/AIDS 
Retrospective Cohort Study
n=953
Integrated data from both Cohort
n=3167
Exclusion (n=693)
- Missing of viral load at initial ART (n=560)
- Missing of CD4 cell count at initial ART (n=41)
- Missing of time to initial ART (n=70)
-  Missing of follow-up duration from initial ART to death or censoring (n=21)
- Missing of age at initial ART (n=1)
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respectively]. Most of the patients (96.3–98.6%) initiated ART 
which consisted of a minimum of two active drugs from two 
classes, highly active ART. About 68.3–79.2% of patients started 
ART during the same period when they were diagnosed with 
HIV infection. The median time from HIV infection diagnosis 
to the start of ART decreased from 3 months (IQR 1–12 months) 
in 2001–2003 to 1 month (IQR 1–9 months) in 2013–2015 (p for 
trend <0.001) (Table 1).
Mortality among people living with HIV/AIDS who 
started ART between 2001 and 2015
Of the 2474 patients who had started ART between 2001 and 
2015, 105 (4.24%) died over a median 3-year follow-up; 11.1% 
(16/144), 5.2% (17/327), 5.5% (34/615), 4.1% (28/686), and 1.4% 
(10/702) of patients died in 2001–2003, 2004–2006, 2007–2009, 
2010–2012, and 2013–2015, respectively.
The overall mortality rate was 10.97 per 1000 patient-years 
(PYS) during the entire study period. There was no significantly 
decreasing trend of mortality in people living with HIV/AIDS 
who received ART between 2001 and 2015 in Korea (p for trend= 
0.624). The mortality rate, according to the period of ART initi-
ation, decreased from 12.64 per 1000 PYS in 2001–2003 to 8.04 
per 1000 PYS in 2004–2006, but then increased until 2012 (12.04 
per 1000 PYS in 2007–2009 and 12.73 per 1000 PYS in 2010–
2012). The most recent mortality rate was 8.59 per 1000 PYS in 
2013–2015 (Table 2). The overall mortality rate was slightly high-
er in 693 patients who were excluded due to missing data (16.77 
per 1000 PYS), and a similar trend of mortality was observed 
among them (Supplementary Table 1, only online). 
Out of 105 deaths, 42 (40%) were AIDS-related (Table 3). Most 
of these deaths were classified as AIDS-related deaths due to 
low CD4 cell counts. The specific causes of AIDS-related deaths 
are shown in Supplementary Table 2 (only online). The propor-
tions of AIDS-related deaths in each period of ART initiation 
were as follows: 50% in 2001–2003, 52.9% in 2004–2006, 14.7% 
in 2007–2009, 46.4% in 2010–2012, and 70% in 2013–2015. Al-
though a decreasing trend was observed in the AIDS-related 
death rate from 2001–2003 to 2007–2009, the “cause unknown” 
category accounted for the highest proportion of causes of death 
in the 2007–2009 period (70.6%). Additionally, the proportion of 
AIDS-related deaths increased over time after the 2007–2009 
period, reaching 70% in 2013–2015. Twenty-four (22.9%) deaths 
were attributable to non-AIDS-related conditions. Malignan-
cy was the most common cause, accounting for 33.3% of non-
AIDS-related deaths. Other causes included acute kidney in-













Female, n (%) 22 (15.3) 29 (8.9) 38 (6.2) 50 (7.3) 42 (6)
Median age at initial ART, yr (IQR) 39 (32–44.5) 40 (32–48) 40 (32–49) 40 (31–50) 36 (28–47)
Median CD4 counts at initial ART, cells/mm3 (IQR) 161 (73.5–303) 170 (55–270) 199 (80–280) 196 (69–310) 273 (108–399)











Initial ART regimen, n (%)
Monotherapy 3 (2.1) 3 (0.9) 5 (0.8) 3 (0.4) 3 (0.4)
Dual therapy 2 (1.4) 2 (0.6) 18 (2.9) 17 (2.5) 7 (1.0)
Highly active ART 139 (96.5) 322 (98.5) 592 (96.3) 666 (97.1) 692 (98.6)
Year of diagnosis, n (%)
≤2000 30 (20.8) 19 (5.8) 28 (4.6) 11 (1.6) 5 (0.7)
2001–2003 114 (79.2) 56 (17.1) 37 (6) 22 (3.2) 9 (1.3)
2004–2006 252 (77.1) 130 (21.1) 54 (7.9) 26 (3.7)
2007–2009 420 (68.3) 110 (16) 27 (3.9)
2010–2012 489 (71.3) 88 (12.5)
2013–2015 547 (77.9)
Median time to treatment, months (IQR) 3 (1–12) 3 (1–12) 3 (1–23) 2 (1–19) 1 (1–9)
HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; IQR, interquartile range.
Table 2. Mortality among People Living with HIV/AIDS Who Started ART 
between 2001 and 2015 in the Korea HIV/AIDS Cohort Study and Korea 














2001–2003 9.7 1266 16 12.64
2004–2006 6 2114 17 8.04
2007–2009 4.3 2825 34 12.04
2010–2012 3 2199 28 12.73
2013–2015 2 1164 10 8.59
Total 3 9568 105 10.97
HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syn-
drome; ART, antiretroviral therapy.
*Mortality rate is the number of deaths per 1000 patient-years.
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jury and peritoneal leiomyomatosis. The proportion of non-
AIDS-related deaths increased from 18.8% in 2001–2003 to 20% 
in 2013–2015. However, the proportion of AIDS-related deaths 
was higher than that of non-AIDS-related deaths across all year 
groups except 2007–2009, for which complete data regarding 
the causes of deaths were not available.
Risk factors for mortality
In the univariate Cox regression analyses, mortality was signifi-
cantly associated with age >40 years, CD4 cell counts of <100 
and of 100–199 cells/mm3, and viral loads >100000 copies/mL 
at the initial ART. The multivariate model showed that age >40 
years (adjusted HR, 3.71; 95% CI, 2.35–5.84) and low CD4 counts 
(<100 cells/mm3: adjusted HR, 2.99; 95% CI, 1.44–6.23) were in-
dependent risk factors for all-cause mortality in patients who 
started ART between 2001 and 2015. However, in the multivari-
ate model, calendar year was not statistically significant (Table 4).
DISCUSSION
We investigated the survival trends of people living with HIV/
AIDS in Korea between 2001 and 2015. The all-cause mortality 
rate did not significantly decrease during the study period. Among 
patients with low CD4 cell counts at the time of ART initiation, 
AIDS-related mortality was a leading cause of death during the 
follow-up period. Multivariate Cox regression analyses showed 
that age >40 years and CD4 cell counts <100 cells/mm3 at initial 
ART were the factors associated with mortality.
In recent decades, ART has demonstrated great efficacy and 
few adverse effects compared to earlier treatment regimens, and 
its use has led to a significant suppression of viral replication. 
The simplicity of these regimens has contributed to improved 
short- and long-term adherence. As a result, AIDS-related mor-
tality and all-cause mortality have continued to decrease, even 
in the late ART era.1 In Korea, the proportion of patients with HIV 
infection receiving ART increased from 72% in 2010 to 83% in 
2017, and the most frequently used ART regimen involved two 
nucleotide reverse transcriptase inhibitors plus one protease 
inhibitor (used in 55.6% of patients; data obtained from Korea 
Health Insurance Review and Assessment Service). To ensure 
that no patient remains untreated due to economic reasons, the 
Korean national health insurance covers HIV-related medical 
expenses for those who are registered in the national system, 






Age at initial ART (yr)
≤40 1355 (54.8) 1
>40 1119 (45.2) 3.83 (2.46–5.95) 3.59 (2.3–5.59)
Sex
Male 2293 (92.7) 1.34 (0.62–2.88) 1.29 (0.59–2.8)
Female 181 (7.3) 1
Median CD4 counts at initial ART (cells/mm³)
<100 706 (28.5) 3.67 (1.74–7.71) 2.56 (1.17–5.61)
100–199 475 (19.2) 1.78 (0.78–4.06) 1.38 (0.59–3.22)
200–349 832 (33.6) 1.43 (0.65–3.17) 1.27 (0.57–2.85)
≥350 461 (18.6) 1
Median viral load counts at initial ART (copies/mL)
<10000 568 (23) 1
10000–100000 1036 (41.9) 1.15 (0.66–2.01) 1.05 (0.59–1.86)
>100000 870 (35.2) 1.92 (1.12–3.27) 1.41 (0.8–2.49)
Year of initial ART
2001–2003 144 (5.8) 1.36 (0.59–3.15) 1.23 (0.53–2.86)
2004–2006 327 (13.2) 1.08 (0.51–2.32) 0.87 (0.4–1.88)
2007–2009 615 (24.9) 1.48 (0.76–2.88) 1.23 (0.62–2.42)
2010–2012 686 (27.7) 1.57 (0.81–3.06) 1.27 (0.65–2.48)
2013–2015 702 (28.4) 1
Median time until starting ART since HIV diagnosis (month)
≤2 1078 (43.6) 1
>2 1396 (56.4) 0.74 (0.51–1.07) 0.98 (0.66–1.45)
HR, hazard ratio; CI, confidence interval; ART, antiretroviral therapy; HIV, hu-
man immunodeficiency virus.
Table 3. Causes of Death among Patients according to Year of Initiating Antiretroviral Therapy in the Korea HIV/AIDS Cohort Study and Korea HIV/
AIDS Retrospective Cohort Study
Causes of death 2001–2003 (n=16) 2004–2006 (n=17) 2007–2009 (n=34) 2010–2012 (n=28) 2013–2015 (n=10)
AIDS, n (%) 8 (50) 9 (52.9) 5 (14.7) 13 (46.4) 7 (70)
Non-AIDS, n (%) 3 (18.8) 7 (41.2) 5 (14.7) 7 (25) 2 (20)
Infection 1 (3.6) 1 (10)
Liver disease 1 (5.9)
Malignancy 2 (11.8) 4 (11.8) 1 (3.6) 1 (10)
Cardiovascular disease 1 (6.3) 1 (5.9) 3 (10.7)
Respiratory disease 2 (12.5) 2 (11.8) 1 (2.9) 1 (3.6)
Accident/suicide/overdose
Others* 1 (5.9) 1 (3.6)
Unknown, n (%) 5 (31.3) 1 (5.9) 24 (70.6) 8 (28.6) 1 (10)
HIV, human immunodeficiency virus; AIDS, acquired immunodeficiency syndrome.
*Other causes included acute kidney injury and peritoneal leiomyomatosis.
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after the confirmation of HIV infection. However, we could not 
observe an improved survival trend in this study, which may 
be explained by the low CD4 cell counts at ART initiation. The 
baseline CD4 cell count at ART initiation is one of the most im-
portant prognostic factors, as low CD4 cell counts at initiation 
are associated with high mortality.14 Domestic guidelines, which 
were revised in 2013, removed the recommendation of a CD4 
count threshold for ART initiation, which may have led to a de-
crease in the median time from HIV infection diagnosis to treat-
ment initiation, as well as increased median CD4 counts at the 
initial ART. Nonetheless, until recently, CD4 cell counts at the 
time of ART initiation remained low in our cohort. One study 
investigated the trends of CD4 cell counts at HIV infection di-
agnosis in Korea, and found that CD4 cell counts at the time of 
HIV infection diagnosis remained low between 2001 and 2015 
(median CD4 cell count at the initial HIV infection diagnosis, 
247 cells/mm3). According to that study, the proportion of pa-
tients with CD4 cell counts ≤200 cells/mm3 at the time of HIV 
infection diagnosis increased gradually, reaching 51% in 2010–
2012.11 These findings indicate that a large proportion of patients 
in Korea continued to start their treatment late due to a delayed 
diagnosis rather than deferred ART.
In contrast to our results, CD4 cell counts at the initial ART 
increased from 173 cells/mm3 before 2007 to 302 cells/mm3 af-
ter 2011 in Asia as a whole.15 The proportion of late presenters 
(defined as patients with CD4 cell count ≤200 cells/mm3 at di-
agnosis) decreased from 79.1% before 2007 to 36.3% after 2011, 
which may have contributed to improved survival over the years 
in this region.16 According to this study, AIDS-related mortality 
was the main cause of death before 2007, but there was a de-
crease in the AIDS-related mortality rate over time. Another 
study based on data from the UK Collaborative HIV Cohort Study 
showed similar results. The proportion of patients with CD4 cell 
count ≤200 cells/mm3 at the start of ART decreased from 67% 
in 1996–1999 to 49% in 2006–2008, and the mortality rate de-
creased during the same period.17
Several factors have been reported to be associated with late 
presentation in Korea.18 Among them, older age was shown to 
be an important factor in previous studies,19-21 as well as in this 
study (Supplementary Table 3, only online). This may be due to 
a lack of knowledge about HIV infection among older patients 
in Korea. Indeed, the current Korean educational and preven-
tive programs regarding HIV infection are primarily targeted 
to adolescents and young adults; therefore, older people may 
have little knowledge about HIV infection. Additionally, the fear 
of stigma may contribute to a delayed diagnosis and treatment. 
According to a 2016 survey by the National Human Rights Com-
mission of Korea, the fear of an HIV infection diagnosis becom-
ing known to others and possible discrimination due to HIV in-
fection were major difficulties for people living with HIV/AIDS.
Our study had several limitations. First, the size of the study 
population was small. However, considering the low prevalence 
of HIV infections in Korea, our data, derived from the largest co-
hort in Korea, were representative of people living with HIV/
AIDS in Korea. Second, we did not include some covariates due 
to missing data. Therefore, the effect of confounding factors was 
not fully controlled. Third, in 2007–2009, the period when the 
cohort had the lowest proportion of AIDS-related deaths during 
the study period, the cause of death accounting for the largest 
proportion of deaths was “unknown.” For mortality data in HIV 
patients, we used the death report data from the AIDS Manage-
ment Division of the KCDC, as well as medical records in the 
hospitals; however, unlike hospital medical records, the death 
report data only indicated whether the patients had died and 
the time of death, but not the cause of death. Since a large pro-
portion of mortality data for 2007–2009 were derived from death 
report data, the causes of death were unknown for the largest 
proportion of deaths in that period. 
Recent guidelines recommend early initiation of ART regard-
less of CD4 cell counts, which confers a survival benefit.10,22,23 
However, CD4 cell counts at the initial ART are still low in Ko-
rea due to late diagnosis. AIDS-related mortality remains the 
leading cause of death, despite excellent HIV care available in 
the recent ART era. Early initiation of ART in patients with high 
CD4 cell counts remains a challenge to the Korean public health 
system. National efforts to reduce the proportion of late pre-
senters must be implemented via the promotion of HIV testing 
among community residents and other vulnerable groups in 
various settings. It is also necessary to increase awareness about 
HIV infection through the expansion of educational and preven-
tive programs directed toward older people and to strengthen 
the linkage to medical institutions, considering the age-specific 
characteristics of the subjects. 
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